📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. (2023)

First Author: Attard G

Attributed to: Evaluating new healthcare technologies in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(23)00148-1

PubMed Identifier: 37142371

Publication URI: http://europepmc.org/abstract/MED/37142371

Type: Journal Article/Review

Volume: 24

Parent Publication: The Lancet. Oncology

Issue: 5

ISSN: 1470-2045